Tolerance and autoimmunity

BMJ

Volumn 321, Issue 7253, 2000, Pages 93-96

  Mackay, Ian R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 4; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; AUTOIMMUNE DISEASE; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIBODY FORMATION; APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; RISK FACTORS;

EID: 0034622276     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7253.93     Document Type: Article

References (30)

1. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223–243.
2. Van Parijs L, Abbas AK. Homeostasis and self tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243–248.
3. Goodnow C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996; 93: 2264–2271.
4. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol 1998; 71: 229–265.
5. Tarlinton D. Germinal centers: a second childhood for lymphocytes. Curr Biol 1997; 7: R155–R159.
6. Nepom GT. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv Immunol 1998; 68: 315–332.
7. Mackay CR. Homing of naive, memory and effector lymphocytes. Curr Opin Immunol 1993; 5: 423–427.
8. Quill J. Anergy as a mechanism of peripheral T cell tolerance. J Immunol 1996; 156: 1325–1327.
9. Greenfield EA, Nguyen KA, Kuchroo VK. C28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389–418.
10. Marelli-Berg FM, Lechler RI. Antigen presentation by parenchymal cells: a route to peripheral tolerance. Immunol Rev 1999; 172: 297–314.
11. Seddon B, Mason D. The third function of the thymus. Immunol Today 2000; 21: 95–99.
12. Granville D, Carthy CM, Hunt DWE, McManus BM. Apoptosis: molecular aspects of cell death and disease. Lab Invest 1998; 78: 893–913.
13. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. Complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525–4528.
14. Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 Fas/APO-1 mutations. Arthritis Rheum 1999; 42: 1833–1842.
15. Horwitz MS, Bradley LM, Harbetson J, Krohl T, Lee J, Sarvetnik N. Diabetes induced by coxsackie virus: initiation by bystander damage and not molecular mimicry. Nature Med 1998; 4: 781–785.
16. Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heart autoantibodies in mice with coxsackie B3- and cardiac myosin-induced autoimmune myocarditis. J Immunol 1994; 152: 343–350.
17. Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12: 1255–1265.
18. Darnell RB. The importance of defining the paraneoplastic neorologic disorders. N Engl J Med 1999; 340: 1831–1833.
19. Todd JA. From genome to aetiology in a multifactorial disease; type 1 diabetes. Bioessays 1999; 21: 164–174.
20. Griffiths MM, Encinas JA, Remmers EF, Kuchroo VK, Wilder RL. Mapping autoimmunity genes. Curr Opin Immunol 1999; 11: 689–700.
21. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263–266.
22. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568–574.
23. Luster AD. Chemokines chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–445.
24. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701–708.
25. Feldman M, Charles P, Taylor P, Maini RN. Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 1998; 20: 211–228.
26. Sayegh MH. Finally, CTLA4Ig graduates to the clinic. J Clin Invest 1999; 103: 1223–1225.
27. Tian J, Olcott A, Hanssen L, Zekzer D, Kaufman D.L., Antigen-based immunotherapy for autoimmune disease: from animal models to humans. Immunol Today 1999; 20: 190–195.
28. Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, et al. Autologous haemopoietic stem cell transplants for autoimmune disease feasibility and transplant-related mortality. Bone Marrow Transplant 1999; 24: 729–734.
29. Porter M, Black C. Bone marrow transplantation for autoimmune diseases. BMJ 1999; 318: 750–751.
30. Giannoukakis N, Rudert WA, Robbins PD, Trucco M. Targeting autoimmune diabetes with gene therapy. Diabetes 1999; 48: 2107–2121.